How has my 'Dandy Dozen' list performed so far? Let's look at the results and my strategy behind them.
CFG offers security, but not necessarily a 'home run' win. Here's how to play it.
Now that uncertainty has made this bank name an opportunity. Let me show you how to play it.
Here's a relatively conservative options play in a communications technology company.
Just like its bubble-wrap, Sealed Air Corp. is ready to make some noise. Let's see how to play it.
The situation for bitcoin investors right now is tough, but as we look at the crypto exchange-traded funds and the digital currency, I see one good 'option.'
If you think NFLX at current prices is a buy, then you better read my lesson on equity investing.
No matter who works the numbers on FORR, reward appears to dwarf risk from this depressed price point.
Revive your portfolio with Baxter International.
Let's see how to trade GlycoMimetics, a clinical-stage drug developer focused on a type of cancer treatment.
Owning PLCE should work out very well, even if the main research houses' conservative fiscal 2023 views prove correct. Here's how to play it.
Sometimes if you want to make money in stocks, you have to bottle up your emotions, especially when the market appears in a 'jam.'
Everything you need to know after Prologis' fourth-quarter results.
I've got a trade in the once popular GoPro -- let's see if it can add life to your portfolio.
Let me show you how with Wolverine Worldwide and Caleres.
Installed Building Products offers incredible growth and an incredibly cheap valuation.
Baxter International is now at the best entry point to date. Let's see how to play it.
Here's how to play G-III Apparel Group after a rough year.
Let me show you my top dollar holdings as we head into 2023, and why I'm making these investments.
Here's how to play Canada-based Masonite International.
After a major 2022 selloff, this REIT should have solid total return prospects. Let's see how to play it.
In this second part of a two-part series, we'll explore balancing the news with the charts, how to avoid jumping the gun, and more.
Just because this couch company has seen some hard times doesn't mean I'm just going to bail out. Right now, it is my 'option.'
Here's why this name is undeservedly, and temporarily, cheap.
This biotech stock holds promise in the new year, whether it's bought out or not.
Here's why I'll be ready to rumble in the new year -- and why you should be, too.
This undervalued savings and loan doesn't pay a dividend but has rewarded shareholders with big returns over the years and looks primed to do so again.
Let's take a look at price action, the king of all technicals.
HighPeak Energy holds promise in this options trade.
I challenge readers to tell me why they think owning this stock makes sense.